Europe Viral Vector Manufacturing Market Report and Forecast 2024-2032

The global viral vector manufacturing market size was valued at USD 2.6 billion in 2023, with Europe holding a significant market share. The market is driven by advancements in gene therapy and vaccine development. It is expected to grow at a CAGR of 20.30% during the forecast period of 2024-2032, with the values likely to attain USD 13.5 billion by 2032.

Key Takeaways

• According to the Alliance for Regenerative Medicine, around 358 gene therapy trials were reported in Europe in 2023, with the total investment in gene therapy estimated to be USD 1.2 billion in the year. The rising focus on gene therapy to treat various diseases is expected to directly impact the market demand.
• The key market players are actively investing in the capacity expansion of their production facilities which is likely to boost Europe viral vector manufacturing market share in coming years. In June 2023, Yposkesi, the viral vector manufacturing subsidiary of SK pharmteco’s (a CDMO) in France, completed its second facility for the manufacture of cell and gene therapies.
• A major market trend is the rise in strategic partnerships between the leading biotechnology companies and contract development and manufacturing organizations (CDMOs). In December 2023, Oxford Biomedica entered into an agreement to acquire ABL Europe S.A.S. from Institut Mérieux SA.

Europe Viral Vector Manufacturing Market Analysis

Viral vectors are increasingly used in research settings to deliver genetic material into cells. They are considered the most effective means to transfer genes, to modify a certain cell type or tissue and manipulate them to produce therapeutic proteins. Besides their application in gene therapy and vaccine development, viral vectors are also being explored in other medical fields such as regenerative medicine, immuno-oncology, and neurological disorders. To accommodate these emerging applications, many pharmaceutical and biotechnology companies are investing to expand their production capabilities, which is expected to significantly contribute to the Europe viral vector manufacturing market growth.

The market is witnessing increased demand for viral vectors, which can be attributed to the growing impetus on gene therapy to treat various diseases. According to the Alliance for Regenerative Medicine (an international advocacy organization working to advance safe and effective regenerative cell therapies), around 358 gene therapy trials were reported in Europe in 2023, with the total investment in gene therapy estimated to be USD 1.2 billion in the year. Thus, to meet the growing demand for gene therapy and keep up with the rising advancements, companies involved in viral vector manufacturing are continuously working towards improving production efficiency and capacity, which is likely to elevate the Europe viral vector manufacturing market value.

In June 2023, the global contract development and manufacturing organization (CDMO) SK pharmteco’s Yposkesi, the viral vector manufacturing subsidiary in France announced the completion of its second facility for the manufacture of cell and gene therapies, particularly specialized for adeno-associated virus (AAV) and lentiviral vectors (LVs) production. Located in the Genopole Campus, the facility is designed with the current (Good Manufacturing Practices) GMP guidelines of Europe and the United States and spans an area of 5,000 square meters. Following the construction of the second cell and gene therapy production, Yposkesi now functions in an area of 10,000 square meters together with the first bioproduction site. The facility will amplify production capacity and help expand the company’s presence in the anti-cancer and immune cell therapy market. Such increased investments to boost production capacity by the major market players is anticipated to augment market share in the coming year.

One of the major Europe viral vector manufacturing market trends is the increased merger and acquisition activities among the leading companies to establish their presence in international markets. In December 2023, Oxford Biomedica (gene and cell therapy biotech company) entered into an agreement to acquire ABL Europe S.A.S. (a pure-play European CDMO) from Institut Mérieux SA (a French holding biotechnology company). The transaction, completed in January 2024, will provide Oxford Biomedica with multi-viral vector CDMO capabilities across multiple sites in the European Union, United States, and United Kingdom as well as offer new facilities in France to improve service for its customers by addressing the demand for process development. Additionally, the acquisition will strengthen the company’s position as the leading cell and gene therapy CDMO. The rise in such strategic partnerships is poised to bolster market growth in the forecast period.

Europe Viral Vector Manufacturing Market Segmentation

Market Breakup by Type

• Adenoviral Vectors
• Adeno-Associated Viral (AAV) Vectors
• Lentiviral Vectors
• Retroviral Vectors
• Others

Market Breakup by Application

• Gene Therapy
• Cell Therapy
• Others

Market Breakup by Type Therapeutic Area

• Oncological Disorders
• Neurological Disorders
• Metabolic Disorders
• Immunological Disorders
• Others

Market Breakup by End User

• Research Organizations
• Biotech and Pharmaceutical Companies
• Others

Market Breakup by Country

• United Kingdom
• Germany
• France
• Italy
• Others

Europe Viral Vector Manufacturing Market: Competitor Landscape

The key features of the market report include funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:

• Lonza Group AG
• Merck KGaA
• Oxford Biomedica
• Novartis AG
• Sartorius AG
• SIRON Biotech
• PlasmidFactory GmbH
• Kaneka Eurogentec S.A.
• Advanced BioScience Laboratories, Inc.
• F. Hoffmann-La Roche AG

Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.

FAQs

What is the Europe viral vector manufacturing market forecast outlook for 2024-2032?
The Europe viral vector manufacturing market is expected to be driven by the rising demand for the global market, which is anticipated to grow at a CAGR of 19.74% during the forecast period of 2024-2032 and is likely to reach a market value of USD 13.5 billion by 2032.

What are the major factors aiding the Europe viral vector manufacturing market demand?
The increasing focus on gene therapy and vaccine development is fuelling the demand for the market.

What are the major Europe viral vector manufacturing market trends?
One of the significant trends in the market is the rise in strategic partnerships between the leading biotechnology companies and contract development and manufacturing organizations (CDMOs). In December 2023, Oxford Biomedica entered into an agreement to acquire ABL Europe S.A.S. from Institut Mérieux SA. The acquisition will strengthen the company’s position as the leading cell and gene therapy CDMO.

What is the market segmentation based on the type?
Based on the type, the market is segmented into adenoviral vectors, adeno-associated viral (AAV) vectors, lentiviral vectors, and retroviral vectors, among others.

What is the market breakup by therapeutic area?
By therapeutic area, the market is divided into oncological disorders, neurological disorders, metabolic disorders, and immunological disorders, among others.

What are the major end users of the market?
End users of the market are research organizations, biotech, and pharmaceutical companies, among others.

What are the applications of the viral vector manufacturing?
Major applications of viral vector manufacturing include gene therapy, cell therapy, and vaccines.

What is the market segmentation by countries?
The market segmentation by countries includes the United Kingdom, Germany, France, and Italy, among others.

Who are the key players involved in the Europe viral vector manufacturing market?
The key players in the market are Lonza Group AG, Merck KGaA, Oxford Biomedica, Novartis AG, Sartorius AG, SIRON Biotech, PlasmidFactory GmbH, Kaneka Eurogentec S.A., Advanced BioScience Laboratories, Inc., and F. Hoffmann-La Roche AG


This product will be delivered within 5-7 business days.